PoNS device along with physical therapy is intended to treat chronic balance deficit caused by mild-to-moderate traumatic brain injury. Credit: digitalbob8.

The US Food and Drug Administration (FDA) has rejected Helius Medical Technologies’ premarket submission for the Portable Neuromodulation Stimulator (PoNS) device due to a lack of data.

Designed to be used in conjunction with physical therapy, PoNS is intended for the treatment of chronic balance deficit caused by mild-to-moderate traumatic brain injury.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Treatment involves the delivery of neuromodulation to stimulate cranial nerves, which is claimed to restore neurological function.

The company filed a submission to the FDA in September last year. Its application included findings from two double-blind, randomised, controlled clinical trials that evaluated the safety and efficacy of PoNS in a total of 163 participants.

"Helius remains committed to generating the data to pursue a de novo classification and 510(k) clearance of our PoNS device in the future."

The regulator has rejected the application stating that it does not have enough evidence that the effects observed in the clinical trials were due to the independent effects of the medical device.

The FDA noted that patients in both the treatment and control arms experienced improvements from baseline for all of the clinical endpoints.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The agency added that the neurotech company can resubmit its application in the future with additional data.

In a press release, Helius Medical said that the FDA’s review did not identify any device-related serious adverse events in the clinical trials.

Helius Medical Technologies CEO Philippe Deschamps said: “We are understandably disappointed by the agency’s decision to decline our request for de novo classification and 510(k) clearance, but Helius remains committed to generating the data to pursue a de novo classification and 510(k) clearance of our PoNS device in the future for the treatment of patients with chronic balance deficit due to mmTBI, in order to bring our innovative therapy to more than 1.5 million Americans suffering from this condition.”

PoNS currently holds regulatory approval in Canada and is being reviewed in the European Union (EU).

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact